Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

NCT00107432 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Epithelial Mesothelioma
Recurrent Malignant Mesothelioma
Sarcomatous Mesothelioma
Stage IA Malignant Mesothelioma
Stage IB Malignant Mesothelioma
Stage II Malignant Mesothelioma
Stage III Malignant Mesothelioma
Stage IV Malignant Mesothelioma

Interventions

DRUG: sorafenib tosylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)